哈三联信披违规收警示函 2024年净利降20%炒股亏1463万元

Core Viewpoint - Harbin Sanlian (哈三联) has faced regulatory penalties for failing to disclose external financial assistance as required, leading to warnings issued by the Heilongjiang Securities Regulatory Bureau against the company and its executives [1] Financial Performance - In 2024, Harbin Sanlian reported a revenue of 1.132 billion yuan, a decrease of 4.58% year-on-year, and a net profit of 58.68 million yuan, down 20.35% year-on-year [2] - The company's net profit decline was attributed to the impact of centralized drug procurement policies, increased competition, and rising operating costs, while the non-recurring net profit increased by 73.85% to 53.23 million yuan [2] - The pharmaceutical segment generated 989 million yuan in revenue, a decline of 13.48%, with a gross margin of 55.34%, down 6.05% year-on-year [3] Securities Investment - Harbin Sanlian recorded a fair value loss of 14.63 million yuan from securities investments in 2024, primarily from holdings in the Hong Kong-listed company, Sihuan Pharmaceutical [3] - The company also reported a fair value change loss of 502.73 thousand yuan, a significant decrease of 236.44% year-on-year [4] Recent Developments - The company has been involved in financial transactions with Harbin Taishengchang Packaging and Printing Co., Ltd. and Zhongfu Pharmaceutical Co., Ltd., totaling 22.5 million yuan and 22 million yuan respectively, which were not fulfilled as per agreements [1]